Opdivo (nivolumab) Market Overview: Major Segments, Strategic Developments, and Leading Companies

The Opdivo (nivolumab) market is set for significant expansion in the coming years, driven by advancements in cancer treatment and increasing demand for innovative therapies. As oncology evolves, this market is positioned to capitalize on new opportunities and broaden its impact across various cancer types. Here is an in-depth look at the market size, key players, emerging trends, and segmentation details.

Projected Market Growth and Size for Opdivo (nivolumab) by 2030
The Opdivo (nivolumab) market is forecasted to experience robust growth, reaching a valuation of $12.13 million by 2030. This represents a compound annual growth rate (CAGR) of 7.7% over the forecast period. Several factors are contributing to this growth, including the expansion into new oncology indications, increased use of combination therapy protocols, greater reliance on biomarker-based patient selection, rising rates of cancer diagnosis, and heightened spending in oncology healthcare. Key market trends anticipated to drive this growth include the broader use of immune checkpoint inhibitors, increased adoption of combination immunotherapy regimens, the expansion of PD-1 targeted cancer treatments, and a stronger emphasis on long-term survival outcomes.

Download a free sample of the opdivo (nivolumab) market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Shaping the Opdivo (nivolumab) Market
The Opdivo (nivolumab) market is primarily dominated by Bristol-Myers Squibb and Ono Pharmaceutical. In a notable development in June 2024, US-based biotechnology firm I-Mab formed a clinical trial collaboration and supply agreement with Bristol Myers Squibb. This partnership aims to investigate I-Mab's bispecific antibody, givastomig, targeting Claudin 18.2 x 4-1BB, in combination with Opdivo (nivolumab) and standard chemotherapy regimens like FOLFOX or CAPOX. The clinical trials focus on first-line treatment options for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Bristol Myers Squibb, headquartered in the US, is the manufacturer of Opdivo (nivolumab).

Emerging Trends Highlighting the Future of the Opdivo (nivolumab) Market
Top players in the market are increasingly concentrating on developing sophisticated combination therapies that aim to boost treatment effectiveness, address resistance issues, and expand the drug's use across various cancer types. Combination therapies typically involve pairing Opdivo (nivolumab) with other treatment agents, such as chemotherapy, to provide a comprehensive approach for patients with advanced cancers. For example, in October 2024, the US Food and Drug Administration approved Opdivo (nivolumab) combined with platinum-doublet chemotherapy as a neoadjuvant treatment. This regimen is followed by single-agent nivolumab as adjuvant therapy after surgery for adults with resectable non-small cell lung cancer (NSCLC) who lack EGFR or ALK mutations. This regulatory approval enables the use of Opdivo both before and after surgery, improving therapeutic outcomes for eligible patients.

View the full opdivo (nivolumab) market report:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Detailed Segmentation of the Global Opdivo (nivolumab) Market
This report categorizes the Opdivo (nivolumab) market based on several segments:
1) By Type: 40 mg/4 mL, 100 mg/10 mL, and 240 mg/24 mL formulations
2) By Dosage Form: Injection, Solution, and other dosage forms
3) By Application: Including indications such as Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), and other uses
4) By End-User: Hospitals, Clinics, and other healthcare providers

This comprehensive segmentation provides a clear view of the market's breadth across product types, therapeutic applications, and healthcare settings globally.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.